As many of you know, we are very bullish on the long-term future of Chinese small cap and mid cap companies for two reasons:
1] The obvious reason – China is the fastest growing economy on the planet and nothing is going to slow down its ascent over the next 50 years and beyond. Investing in growth companies there just makes too much sense.
2] Great Results and Valuations - Despite some real problems in the Chinese small-cap space, we continue to believe that too many companies have suffered from “babies being thrown out with the bathwater” syndrome. Investors have to remain patient and wait for the smoke to clear – but when it does we see a great opportunity to profit from the real companies that have been left standing. As such, we’re going to continue reporting and remaining patient.
TODAY’S FEATURED COMPANY
China BCT is engaged in pharmaceutical distribution, pharmacy retailing, and the manufacture of pharmaceuticals products through its subsidiaries Guangxi Liuzhou Baicaotang Medicine Limited, Guangxi Liuzhou Baicaotang Medicine Retail Limited, and Hefeng Pharmaceutical Co. Limited in Guangxi province, China. It operates a large regional retail network in Guangxi province, consisting of 219 directly owned retail stores in Guangxi province and currently over 8,000 products are distributed through the Company’s wholesale distribution network.
On March 30th 2012 the company announced results for the fourth quarter and full year ended December 31, 2011
Fourth Quarter 2011 Highlights
- Revenue decreased 0.7% year-over-year to $66.3 million
- Gross profit rose 12.2% year-over-year to $15.8 million
- Operating income grew 0.5% year-over-year to $9.5 million
- GAAP net income declined 7.1% to $6.9 million, or $0.18 per diluted share, from $7.4 million, or $0.19 per diluted share, in the year ago quarter
- Excluding non-cash items related to change in the fair value of warrant liabilities and share-based compensation expense, non-GAAP adjusted net income was $7.8 million, or $0.21 per diluted share
- Cash and cash equivalents as of December 31, 2011 totaled $31.5 million, compared to $20.2 million at the end of 2010
Full Year Highlights;
- Revenue was $257.5 million for the twelve months ended December 31, 2011, an increase of 28.2% from $200.8 million in the prior year.
- Gross profit was $61.8 million, or 24.0% of revenue, up 26.6% from $48.8 million, or 24.3% of revenue, for the year ended December 31, 2010.
- Operating income was $42.2 million, or 16.4% of revenue, up 19.2% from $35.4 million, or 17.6% of revenue in 2010.
- Net income increased 22.1% to $31.2 million, or $0.82 per diluted share, compared to $25.7 million, or $0.67 per diluted share prior year.
YOUR RESEARCH STARTING POINTS FOR CHINESE SMALL CAP AND MID CAP COMPANIES
We’ve provided investors with two great starting points to research great Chinese small cap and mid cap companies.
1. ChinaSecurities.com – ChinaSecurities.com tracks 250 of the best small cap and mid cap companies trading on North American exchanges. It provides you with the best of the best in two ways. First, the front page lists the best news of the day coming out of the space. It does so by giving you a text view of the best press releases by industry and via Chinese Stocks TV, a 5-minute broadcast every morning just after the open. Chinese Stocks TV is archived, so you can catch up on shows you missed.
Second, if you want to research each of the 250 companies to find candidates for your portfolio, it has a very intuitive directory that lets you quickly review each company on the master list, or parse it out by industry and exchange if you have a particular sector of interest. Cool stuff.
2. Right here on AGORACOM, you can refer to our China category for other featured Chinese Small-Cap Companies. As always, we will disclose any IR relationship with any public company. Given the sheer number of great Chinese Small-Cap Companies out there, you can expect us NOT to have an IR relationship with most of these companies.